|1.||Fukushima, Masakazu: 5 articles (09/2011 - 06/2006)|
|2.||Yano, Koji: 2 articles (01/2015 - 04/2007)|
|3.||Luo, Zhibin: 2 articles (01/2014 - 05/2013)|
|4.||Zhao, Hong: 2 articles (01/2014 - 05/2008)|
|5.||Meng, Cuicui: 2 articles (01/2014 - 05/2013)|
|6.||Kohno, Shigeru: 2 articles (02/2013 - 06/2002)|
|7.||Liu, He-ying: 2 articles (10/2012 - 04/2012)|
|8.||Zhu, He: 2 articles (10/2012 - 04/2012)|
|9.||Chu, Yan: 2 articles (10/2012 - 04/2012)|
|10.||Ding, Li: 2 articles (10/2012 - 04/2012)|
|1.||Colorectal Neoplasms (Colorectal Cancer)
09/01/2015 - "Tegafur gimeracil oter combined with oxaliplatin for advanced colorectal cancer."
05/01/2008 - "An oral combined fluoropyrimidine, S-1 (tegafur, gimeracil and oteracil) has recently been used alone or in combination for colorectal cancer (CRC). "
09/01/2007 - "The safety and efficacy of combination therapy with 7-ethyl-10-[4-[1-piperidino]-1-piperidino]carbonyloxycamptothecin (CPT-11, irinotecan) and S-1 composed of tegafur, a prodrug of 5-fluorouracil, gimeracil, and potassium oxonate, have been confirmed in patients with colorectal cancer. "
01/01/2012 - "Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil and oteracil potassium) for colorectal cancer."
04/01/2015 - "The aim of this study was to evaluate the therapeutic efficacy and toxicity of a combination of tegafur-gimeracil-oteracil potassium capsules (S-1) with oxaliplatin for treatment of advanced or recurrent colorectal cancer. "
11/01/2010 - "Gimeracil, a component of S-1, may enhance the antitumor activity of X-ray irradiation in human cancer xenograft models in vivo."
10/01/1999 - "Therefore, to overcome these metabolic events, S-1, an antitumor agent was developed, based on the biochemical modulation of FT by 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate (Oxo), in a molar ratio of 1:0.4:1. The antineoplastic effect of S-1, was examined in Japanese patients with advanced gastric (G) or colorectal (C) cancer in a multicenter early phase II study involving 24 centers throughout Japan. "
09/01/2011 - "Gimeracil was originally added to an oral fluoropyrimidine derivative S-1 to yield prolonged 5-fluorouracil concentrations in serum and tumor tissues. "
11/01/2010 - "Furthermore, we observed decreased expression of γ-H2AX protein, a marker of DNA repair, in LC-11 tumors treated with X-ray irradiation and gimeracil compared to that observed in tumors treated with X-ray irradiation alone, suggesting that gimeracil may inhibit rapid repair of X-ray-induced DNA damage in tumors. "
04/01/2007 - "Pharmacokinetic analysis in this patient on low-dose TS-1 showed that Cmax and AUC of 5-chloro-2,4-dihydroxypyridine (CDHP) were equivalent to the values reported in cancer patients with normal renal function receiving standard-dose administration. "
|3.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
02/01/2010 - "Feasibility study of postoperative adjuvant chemotherapy with S-1 (tegaful, gimeracil, oteracil potassium) for non-small cell lung cancer-LOGIK 0601 study."
07/01/2009 - "Ltd.; Tokyo, Japan) is a new oral fluoropyrimidine formulation that combines tegafur, 5-chloro-2,4-dihydroxypyridine (CDHP), and potassium oxonate in a molar ratio of 1:0.4:1. Single-agent S-1 has demonstrated marked activity against non-small-cell lung cancer (NSCLC) as well as a broad array of other solid tumors, including gastric, colorectal, breast, cervical, and pancreatic cancers. "
07/01/2010 - "The effectiveness of tegafur-gimeracil-oteracil potassium in advanced non-small cell lung cancer (NSCLC) is now under investigation in a phase III trial in the first-line treatment in combination with platinum agent as well as in second-line treatment as monotherapy. "
|4.||Head and Neck Neoplasms (Head and Neck Cancer)
|5.||Stomach Neoplasms (Stomach Cancer)
05/01/2013 - "Another randomised, unblinded trial compared tegafur + gimeracil + oteracil versus flurorouracil monotherapy in 1029 patients with gastric cancer, which was often metastastic. "
05/01/2013 - "An oral fixed-dose combination of tegafur + gimeracil + oteracil (Teysuno degrees, Nordic) has been approved in the European Union for the treatment of advanced gastric cancer. "
06/01/2011 - "To evaluate the efficacy, safety and pharmacokinetic profiles of S-1, which composed of tegafur (FT, a prodrug of 5-FU), 5-chloro-2,4-dihydroxypyridine and potassium oxonate (Oxo), in Taiwanese advanced gastric cancer (AGC) patients. "
10/01/2007 - "Synergistic antitumor effect of combined 5-fluorouracil (5-FU) with 5-chloro-2,4-dihydroxypyridine on 5-FU-resistant gastric cancer cells: possible role of a dihydropyrimidine dehydrogenase-independent mechanism."
10/01/2012 - "The study is to investigate the pharmacokinetics of S-1 capsule (tegafur, gimeracil and potassium oxonate capsule) in patients with advanced gastric cancer after single and multiple oral administration. "
|10.||Dihydrouracil Dehydrogenase (NADP) (Dihydropyrimidine Dehydrogenase)
|1.||Heterologous Transplantation (Xenotransplantation)
|3.||Drug Therapy (Chemotherapy)
|4.||Combination Drug Therapy (Combination Chemotherapy)